Next Article in Journal
Oral Delivery of Biologics via the Intestine
Next Article in Special Issue
Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience
Previous Article in Journal
Antibacterial Layer-by-Layer Coatings for Medical Implants
Previous Article in Special Issue
Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
Review

Focused Ultrasound and Microbubbles-Mediated Drug Delivery to Brain Tumor

by 1,2, 1,2,3, 1,2 and 1,2,4,*
1
Physical Sciences Platform, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada
2
Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
3
Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan
4
Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada
*
Author to whom correspondence should be addressed.
Pharmaceutics 2021, 13(1), 15; https://doi.org/10.3390/pharmaceutics13010015
Received: 21 November 2020 / Revised: 21 December 2020 / Accepted: 22 December 2020 / Published: 24 December 2020
(This article belongs to the Special Issue Drug Delivery to Brain Tumors)
The presence of blood–brain barrier (BBB) and/or blood–brain–tumor barriers (BBTB) is one of the main obstacles to effectively deliver therapeutics to our central nervous system (CNS); hence, the outcomes following treatment of malignant brain tumors remain unsatisfactory. Although some approaches regarding BBB disruption or drug modifications have been explored, none of them reach the criteria of success. Convention-enhanced delivery (CED) directly infuses drugs to the brain tumor and surrounding tumor infiltrating area over a long period of time using special catheters. Focused ultrasound (FUS) now provides a non-invasive method to achieve this goal via combining with systemically circulating microbubbles to locally enhance the vascular permeability. In this review, different approaches of delivering therapeutic agents to the brain tumors will be discussed as well as the characterization of BBB and BBTB. We also highlight the mechanism of FUS-induced BBB modulation and the current progress of this technology in both pre-clinical and clinical studies. View Full-Text
Keywords: blood–brain barrier (BBB); blood–brain–tumor barrier (BBTB); central nervous system (CNS); convention-enhanced delivery (CED); focused ultrasound (FUS) blood–brain barrier (BBB); blood–brain–tumor barrier (BBTB); central nervous system (CNS); convention-enhanced delivery (CED); focused ultrasound (FUS)
Show Figures

Figure 1

MDPI and ACS Style

Wu, S.-K.; Tsai, C.-L.; Huang, Y.; Hynynen, K. Focused Ultrasound and Microbubbles-Mediated Drug Delivery to Brain Tumor. Pharmaceutics 2021, 13, 15. https://doi.org/10.3390/pharmaceutics13010015

AMA Style

Wu S-K, Tsai C-L, Huang Y, Hynynen K. Focused Ultrasound and Microbubbles-Mediated Drug Delivery to Brain Tumor. Pharmaceutics. 2021; 13(1):15. https://doi.org/10.3390/pharmaceutics13010015

Chicago/Turabian Style

Wu, Sheng-Kai; Tsai, Chia-Lin; Huang, Yuexi; Hynynen, Kullervo. 2021. "Focused Ultrasound and Microbubbles-Mediated Drug Delivery to Brain Tumor" Pharmaceutics 13, no. 1: 15. https://doi.org/10.3390/pharmaceutics13010015

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop